{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:46:40Z","timestamp":1785322000600,"version":"3.55.0"},"reference-count":29,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006507","name":"Funda\u00e7\u00e3o Oswaldo Cruz","doi-asserted-by":"crossref","award":["Programa Inova (9\/2022)"],"award-info":[{"award-number":["Programa Inova (9\/2022)"]}],"id":[{"id":"10.13039\/501100006507","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,1,20]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      This study assessed the feasibility of implementing a phase 3 field-based clinical trial protocol to evaluate paediatric praziquantel (PED-PZQ) for the treatment of\n                      <jats:italic>Schistosoma mansoni<\/jats:italic>\n                      infection in children aged 3 months to 6 years in endemic areas of Brazil, focusing on operational aspects such as recruitment logistics, documentation management, investigational product handling and protocol adherence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Pilot and feasibility study for a phase 3 clinical trial, comprising two components: a randomised, open-label, parallel-group, two-arm trial and a single-arm trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Conde, Bahia, Brazil, from December 2024 to January 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>\n                      Two trials aim to screen 5774 participants from three rural areas in Bahia and three in Sergipe, states in northeastern Brazil, and enrol 403 children eligible for either randomisation or allocation. Trial 1 will randomise (1:1 ratio) 240 children aged 4\u20136 years into the PED-PZQ treatment arm or the standard praziquantel (PZQ) 1. Trial 2 will enrol 163 children aged 3 months to 3 years, all receiving PED-PZQ. Both trials are open label. Eligible participants shall meet age criteria, test positive for\n                      <jats:italic>S. mansoni<\/jats:italic>\n                      and fulfil other inclusion criteria. In the first recruiting centre, Conde (Bahia), it was estimated that 650 participants would need to be screened for trial 1 and 552 for trial 2, assuming schistosomiasis prevalence of 5% and 4%, respectively. This pilot study reports on the first 60 participants enrolled.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>\n                      The primary outcome of this pilot study is the feasibility of implementing the research protocol in a real-world field setting, focusing on key aspects such as study documentation challenges, participant safety, investigational medicinal product custody chain and protocol adherence. In addition to providing preliminary data on the parasitological cure rate, secondary outcomes include the prevalence of\n                      <jats:italic>S. mansoni<\/jats:italic>\n                      infection and the reduction in\n                      <jats:italic>S. mansoni<\/jats:italic>\n                      egg count (Kato-Katz method). Furthermore, the occurrence and severity of drug-related adverse events are monitored from drug administration to day 21 post-treatment, alongside changes in renal, hepatic and cardiac functions assessed through biochemical markers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 60 participants were recruited, and 55 provided stool samples for screening. The pilot phase demonstrated the feasibility of implementing the clinical protocol under field conditions, with successful completion of all planned procedures and minimal protocol deviations. Operational challenges were identified mainly in documentation processes, participant recruitment and investigational product management and were addressed through preventive and corrective quality assurance actions. The experience also highlighted logistical and infrastructural barriers typical of field-based trials in remote endemic areas, which informed adjustments for the subsequent phase 3 study. Preliminary parasitological results indicated an overall\n                      <jats:italic>S. mansoni<\/jats:italic>\n                      prevalence of 9.1% (5\/55), with 21% in trial 1 and 2.8% in trial 2. All infected participants met the eligibility criteria, received treatment and completed follow-up. Four achieved a parasitological cure, and one case of treatment failure was observed (trial 1, PZQ group). Two mild adverse events (diarrhoea) were reported, with no serious complications or clinically significant changes in biochemical parameters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This pilot study demonstrated the feasibility of implementing a field-based phase 3 clinical trial protocol for PED-PZQ in endemic areas of Brazil. The findings confirm that the protocol can be successfully applied in primary care settings, despite operational challenges related to recruitment, logistics and documentation. The study also provided preliminary evidence supporting the safety and effectiveness of the paediatric formulation and highlighted the need to revise prevalence assumptions to improve future screening strategies. Overall, the experience offers valuable insights to guide the large-scale phase 3 trial and supports the incorporation of PED-PZQ into national schistosomiasis control policies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>Brazilian Clinical Trials Registry; RBR-86kcy37.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-104706","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:51:16Z","timestamp":1770299476000},"page":"e104706","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Feasibility of a phase 3 partially randomised clinical trial to assess the safety and efficacy of paediatric praziquantel for schistosomiasis treatment in children aged 3 months to 6 years in endemic regions of Brazil: a pilot study"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7229-4656","authenticated-orcid":false,"given":"Camilla Almeida","family":"Menezes","sequence":"first","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3319-3486","authenticated-orcid":false,"given":"Ane Caroline","family":"Casaes","sequence":"additional","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3630-9187","authenticated-orcid":false,"given":"Brenda Rodrigues Brito Cunha","family":"Silva","sequence":"additional","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4781-7534","authenticated-orcid":false,"given":"Maria Gabriella","family":"Brito dos Santos","sequence":"additional","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9456-5004","authenticated-orcid":false,"given":"Caio Daroz","family":"Martins","sequence":"additional","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7548-0120","authenticated-orcid":false,"given":"Ivia Mayana","family":"Oliveira Francisco","sequence":"additional","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keila Ramos","family":"dos Santos","sequence":"additional","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3302-292X","authenticated-orcid":false,"given":"Bruna Oliveira Lopes","family":"Souza","sequence":"additional","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3861","authenticated-orcid":false,"given":"Alan Gualberto Souza Freitas","family":"Pinho","sequence":"additional","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2735-342X","authenticated-orcid":false,"given":"Dhara Marina Oliveira Brito","family":"Mayer","sequence":"additional","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisella Pinto da Rocha Martinelli","family":"Moleiro","sequence":"additional","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8241-8828","authenticated-orcid":false,"given":"Lorena Concei\u00e7\u00e3o","family":"de Queiroz","sequence":"additional","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramila Marques","family":"Nascimento","sequence":"additional","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseanne Oliveira","family":"Silva","sequence":"additional","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robson da Paix\u00e3o","family":"de Souza","sequence":"additional","affiliation":[{"name":"Universidade Federal da Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano Kalabric","family":"Silva","sequence":"additional","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitermayer Galv\u00e3o","family":"Reis","sequence":"additional","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Graeff-Teixeira","sequence":"additional","affiliation":[{"name":"Universidade Federal do Esp\u00edrito Santo Centro de Ci\u00eancias da Sa\u00fade, Vitoria, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5576-3214","authenticated-orcid":false,"given":"Silvio Santana","family":"Dolabella","sequence":"additional","affiliation":[{"name":"Universidade Federal de Sergipe, S\u00e3o Crist\u00f3v\u00e3o, SE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia Cristina","family":"Carneiro","sequence":"additional","affiliation":[{"name":"Vice-Presid\u00eancia de Pesquisa e Cole\u00e7\u00f5es Biol\u00f3gicas (VPPCB), Funda\u00e7\u00e3o Oswaldo Cruz, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0290-6808","authenticated-orcid":false,"given":"Tatiana Camilo Ribeiro","family":"de Senna","sequence":"additional","affiliation":[{"name":"Vice-Presid\u00eancia de Pesquisa e Cole\u00e7\u00f5es Biol\u00f3gicas (VPPCB), Funda\u00e7\u00e3o Oswaldo Cruz, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9747-0222","authenticated-orcid":false,"given":"Andre","family":"Daher","sequence":"additional","affiliation":[{"name":"Vice-Presid\u00eancia de Pesquisa e Cole\u00e7\u00f5es Biol\u00f3gicas (VPPCB), Funda\u00e7\u00e3o Oswaldo Cruz, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Lacerda","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Farmanguinhos, Funda\u00e7\u00e3o Oswaldo Cruz, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Johansson Soares","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Farmanguinhos, Funda\u00e7\u00e3o Oswaldo Cruz, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-7718","authenticated-orcid":false,"given":"Fernando Schemelzer de Moraes","family":"Bezerra","sequence":"additional","affiliation":[{"name":"Universidade Federal do Cear\u00e1, Fortaleza, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-4099","authenticated-orcid":false,"given":"Isadora Cristina","family":"de Siqueira","sequence":"additional","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-2313","authenticated-orcid":false,"given":"Ricardo Riccio","family":"Oliveira","sequence":"additional","affiliation":[{"name":"FIOCRUZ Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"2026062610405301000_16.2.e104706.1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4269\/ajtmh.2012.11-0204","article-title":"Factors Associated with Resistance to Schistosoma mansoni Infection in an Endemic Area of Bahia, Brazil","volume":"86","author":"Oliveira","year":"2012","journal-title":"The American Society of Tropical Medicine and Hygiene"},{"key":"2026062610405301000_16.2.e104706.2","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade . Secretaria de vigil\u00e2ncia em sa\u00fade e ambiente. departamento de doen\u00e7as transmiss\u00edveis. vigil\u00e2ncia da esquistossomose mansoni: diretrizes t\u00e9cnicas. Bras\u00edlia; 2024."},{"key":"2026062610405301000_16.2.e104706.3","unstructured":"World Health Organization . Ending the neglect to attain the sustainable development goals: a rationale for continued investment in tackling neglected tropical diseases 2021\u20132030. Geneva, 2020."},{"key":"2026062610405301000_16.2.e104706.4","unstructured":"World Health Organization . WHO guideline on control and elimination of human schistosomiasis. Geneva, 2022."},{"key":"2026062610405301000_16.2.e104706.5","unstructured":"Funda\u00e7\u00e3o Oswaldo Cruz . Farmanguinhos praziquantel. rio de. Rio de Janeiro; 2021."},{"key":"2026062610405301000_16.2.e104706.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04167.x"},{"key":"2026062610405301000_16.2.e104706.7","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1473-3099(23)00048-8","article-title":"Efficacy, safety, and palatability of arpraziquantel (L-praziquantel) orodispersible tablets in children aged 3 months to 6 years infected with Schistosoma in C\u00f4te d\u2019Ivoire and Kenya: an open-label, partly randomised, phase 3 trial","volume":"23","author":"N\u2019Goran","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026062610405301000_16.2.e104706.8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/cts.12601","article-title":"Relative Bioavailability of Orally Dispersible Tablet Formulations of Levo- and Racemic Praziquantel: Two Phase I Studies","volume":"12","author":"Bagchus","year":"2019","journal-title":"Clin Transl Sci"},{"key":"2026062610405301000_16.2.e104706.9","doi-asserted-by":"crossref","DOI":"10.1590\/0037-8682-0335-2020","article-title":"New epidemiological profile of schistosomiasis from an area of low prevalence in Brazil","volume":"53","author":"Santos","year":"2020","journal-title":"Rev Soc Bras Med Trop"},{"key":"2026062610405301000_16.2.e104706.10","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1400585","article-title":"Navigating the challenges of clinical trial professionals in the healthcare sector","volume":"11","author":"Peralta","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2026062610405301000_16.2.e104706.11","unstructured":"ICH . Guideline for good clinical practice E6(R2). Tinsukia; 2016."},{"key":"2026062610405301000_16.2.e104706.12","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-8-18","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"8","author":"Schulz","year":"2010","journal-title":"BMC Med"},{"key":"2026062610405301000_16.2.e104706.13","unstructured":"ReBEC - Registro Brasileiro de Ensaios C\u00ednicos . RBR-86kcy37 assessment of praziquantel medication for children living in areas where schistosomiasis is common in bahia and sergipe. 2024. Available: https:\/\/ensaiosclinicos.gov.br\/rg\/RBR-86kcy37 [Accessed 4 Nov 2025]."},{"key":"2026062610405301000_16.2.e104706.14","unstructured":"Chow S-C , Shao J , Wang H , et al . Sample size calculations in clinical research. In: Series: Chapman & Hall\/CRC Biostatistics Series | \u201cA CRC Title, Part of the Taylor & Francis Imprint, a Member of the Taylor & Francis Group, the Academic Division of T&F Informa Plc.\u201d: Chapman and Hall\/CRC. 3rd edn. Boca Raton\u202f: Taylor & Francis, 2017."},{"key":"2026062610405301000_16.2.e104706.15","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-15-264","article-title":"Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study","volume":"15","author":"Teare","year":"2014","journal-title":"Trials"},{"key":"2026062610405301000_16.2.e104706.16","first-page":"397","article-title":"A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni","volume":"14","author":"Katz","year":"1972","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"2026062610405301000_16.2.e104706.17","doi-asserted-by":"publisher","DOI":"10.1007\/s10488-010-0319-7"},{"key":"2026062610405301000_16.2.e104706.18","unstructured":"Division of AIDS, National Institute of allergy and infectious diseases, national institutes of health . Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. 2017."},{"key":"2026062610405301000_16.2.e104706.19","unstructured":"World Health Organization . The use of the WHO-UMC system for standardized case causality assessment. Geneva, 2013."},{"key":"2026062610405301000_16.2.e104706.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-023-09238-5","article-title":"\u201cHow do I keep this live in my mind?\u201d Allied Health Professionals\u2019 perspectives of barriers and enablers to implementing good clinical practice principles in research: a qualitative exploration","volume":"23","author":"Wenke","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"2026062610405301000_16.2.e104706.21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s43441-024-00719-1","article-title":"Risk-Based Quality Management: A Case for Centralized Monitoring","volume":"59","author":"Stansbury","year":"2025","journal-title":"Ther Innov Regul Sci"},{"key":"2026062610405301000_16.2.e104706.22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1055\/s-0037-1621702","article-title":"Exploring Data Quality Management within Clinical Trials","volume":"9","author":"Houston","year":"2018","journal-title":"Appl Clin Inform"},{"key":"2026062610405301000_16.2.e104706.23","unstructured":"Amusan E , Emuoyibofarhe J , Arulogun O . Development of a Medical Tele-Management System for Post-Discharge Patients of Chronic Diseases in Resource-Constrained Settings. 2018."},{"key":"2026062610405301000_16.2.e104706.24","unstructured":"Instituto Brasileiro de Geografia e Estat\u00edstica . Estimativas da popula\u00e7\u00e3o. IBGE; 2021. Available: https:\/\/www.ibge.gov.br\/estatisticas\/sociais\/populacao\/9103-estimativas-de-populacao.html [Accessed 4 May 2025]."},{"key":"2026062610405301000_16.2.e104706.25","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.4103\/sja.SJA_559_18","article-title":"The CONSORT statement","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"key":"2026062610405301000_16.2.e104706.26","unstructured":"World Medical Association . Declaration of Helsinki \u2013 ethical principles for medical research involving human subjects. Helsinki, 2024."},{"key":"2026062610405301000_16.2.e104706.27","unstructured":"Organiza\u00e7\u00e3o Pan-Americana da Sa\u00fade. Boas pr\u00e1ticas cl\u00ednicas: Documento das Am\u00e9ricas. 2005."},{"key":"2026062610405301000_16.2.e104706.28","unstructured":"Brasil . Presid\u00eancia Da Rep\u00fablica. Lei No 14.874, de 28 de Maio de 2024. Bras\u00edlia, 2024."},{"key":"2026062610405301000_16.2.e104706.29","unstructured":"Conselho Nacional de Sa\u00fade . Resolu\u00e7\u00e3o cns no 466, de 12 de dezembro de 2012. aprova diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos. Bras\u00edlia; 2013."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-104706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:42:40Z","timestamp":1782495760000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-104706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,5]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bmjopen-2025-104706"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-104706","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}